Technology

technology

Play Video

What are exosomes?

Exosomes are powerful cellular vesicles released by all cells into biofluids (plasma/serum, urine, cerebrospinal fluid and saliva). Exosomes contain multiple geneomic components including RNA, mRNA, microRNA, IncRNA and other RNA species, as well as DNA and proteins from their cells of origin. 

Biofluid exosomes are particularly useful for molecular profiling because they occur in primary and metastatic cancer, as well as in inflammatory, metabolic, cardiovascular, neurodegenerative and other disease processes. 

Proprietary platform for isolating exosomes from urine

While there are a number of different techniques that can be applied to isolate exosomes and other microvesicles from urine, our proprietary platform captures and purifies exosomes and achieves high-quality exosomal RNA isolation.

The leaders in harnessing the power of exosomes

Exosome Diagnostics is the leader in harnessing the power of exosomes and other microvesicles to develop diagnostic tests to better inform the diagnosis, detection, treatment and monitoring of cancer and other diseases. Our Chief Scientific Officer and Founding Scientist, Johan Skog, PhD, was the first to demonstrate that molecular mutations in a tumor could be detected in RNA extracted from exosomes and that this information could be used diagnostically.

With our exosome-based technology, we can achieve real-time access to comprehensive molecular information from cells in the body without the need for tumor tissue sampling (biopsy) or removal.

Technology that's optimized for the clinical workflow

We are well-equipped to meet the needs of physicians and patients by providing the highest quality results to help guide treatment plans. Our test can be easily integrated into the clinical office workflow; from sample collection through results delivery. 

The process of collecting urine is routine, easy, efficient, practical and cost-effective for clinicians to manage. Once a sample arrives at our CLIA laboratory the process is streamlined allowing for efficient turnaround time and reporting.

Additional Resources

A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy

JAMA Oncol 2017, 2(7): 882-889
doi: 10.1001/jamaoncol.2016.0097
https://jamanetwork.com/journals/jamaoncology/
Authors: James McKiernan, Michael Donovan, Vince O’Neill, Stefan Bentnik, Mikkel Noerholm, Susan Belzer, Johan Skog, Michael Kattan, Alan Partin, Gerald Andriole, Gordon Brown, John T. Wei, Ian M. Thompson, Peter Carroll


Liquid biopsy for cancer screening, patient stratification and monitoring

Translational Cancer Research, Vol 4, No 3 (June 2015): 280-290
doi: 10.3978/j.issn.2218-676X.2015.06.05
http://www.thetcr.org/article/view/4546
Authors: Graham Brock, Elena Castellanos-Rizaldos, Lan Hu, Christine Coticchia, Johan Skog


Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease

Kidney International 78, 191–199 (July (2) 2010)
doi: 10.1038/ki.2010.106
http://www.nature.com/ki/journal/v78/n2/full/ki2010106a.html
Authors: Kevin C Miranda, Daniel T Bond, Mary McKee, Johan Skog, Teodor G Păunescu, Nicolas Da Silva, Dennis Brown and Leileata M Russo


Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

Nature Cell Biology 10, 1470–1476 (2008); Published online: 16 November 2008
doi: 10.1038/ncb1800
http://www.nature.com/ncb/journal/v10/n12/abs/ncb1800.html
Authors: Johan Skog, Tom Würdinger, Sjoerd van Rijn, Dimphna H. Meijer, Laura Gainche, William T. Curry, Jr., Bob S. Carter, Anna M. Krichevsky and Xandra O. Breakefield


To view moreclick here 

Development of a clinical implementation plan (CarePath) for a novel urine exosome gene expression assay as part of a two cohort, adaptive decision impact utility trial 

Presented at: American Urological Association (AUA) Annual Meeting 2018 – San Francsico, CA

Authors: McKiernan J, Donovan MJ, Margolis A, Partin A, Carter B, Brown A, Torkler P, Noerholm M, Bentis C, Skog J, Shore N, Andriole G, Etzioni R, Thompson I, Carroll P.

View poster


Extended validation results from a prospective adaptive utility trial confirm performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy

Presented at: American Urological Association (AUA) Annual Meeting 2018 – San Francsico, CA

Authors: McKiernan J, Donovan MJ, Margolis A, Partin A, Carter B, Brown A, Torkler P, Noerholm M, Bentis C, Skog J, Shore N, Andriole G, Etzioni R, Thompson I, Carroll P.

View poster


Performance of a Clinically Validated Urine Exosome Gene Expression Test to Predict High-Grade Prostate Cancer in Men with a Prior Negative Biopsy

Presented at: ASCO GU – San Francisco, 2018

View poster


 

Redical Protatectomy Outcomes from a Validated Urine Exosome Gene Expression Assay Which Predicts High-Grade (GS7) Prostate Cancer Suggests Utility for Men Enrolled in Active Surveillance 

Presented at: American Urology Association (Boston, 2017)

Authors: M Donova, P Torkler, C Bentis, M Noerholm, J Skog, J McKiernan

View poster


 

Performance of a Validated Urine Exosome Gene Expression Assay to Predict High-Grade Postate Cancer Utilizing the ‘International Society of Urological Pathology’ (ISUP) 2014 Grading System

Presented at: ASCO GU (Orlando, 2017)

Authors: M Donaovan, P Torkler, J Skog, B Tissel, M Noerholm, P Carroll

View poster


 

Extended Analysis of a validated urine-exosome signature to predict high grade prostate cancer on initial biopsy maintains performance across multiple sub-groups

Presented at: 2016 Genitourinary Cancers Symposium, (San Francisco, CA; January 2016)
Authors: M. Donovan, S. Bentink, K, M. Noerholm, V. O’Neill, J. Skog

View poster


 

A non-invasive urine exosome gene expression assay (ExoIntelliScoreTM Prostate) accurately predicts pathological stage and grade in the prostatectomy specimen

Presented at: 2016 Genitourinary Cancers Symposium, (San Francisco, CA; January 2016)
Authors: M. Donovan, J. Eastham, V. Patel, J. McKiernan, M. Noerholm, S. Belzer, S. Bentink, J. Skog, V. O’Neill

View poster


 

A non-invasive urine exosome gene expression assay (ExoIntelliScore™ Prostate) accurately predicts pathologic stage and grade in the prostatectomy specimen

Presented at: 18th European Cancer Congress, (Vienna, Austria; September 2015)
Authors: J. Hurley, L. Hu, G. Brock, I. Sinclair, R. Sullivan, V. O’Neill, J. Skog, K. Flaherty

View poster


 

Interim performance of a non-DRE urine exosome gene signature to predict Gleason ≥7 prostate cancer on initial prostate needle biopsy from patients enrolled in a prospective observational trial

Presented at: 2015 American Society of Clinical Oncology Annual Meeting (Chicago, Illinois; May 2015)
Authors: M. J. Donovan, M. Noerholm, S. Bentink, S. Belzer, J. Skog, G. A. Brown, J. S. Cochran, V. O’Neill

View poster


 

Validation of a Novel Non-Invasive Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients Undergoing Initial Biopsy with an Equivocal PSA

Presented at: 2015 American Urological Association Annual Meeting
Presenter: Dr. James McKiernan

View abstract


 

A first catch, non-DRE urine exosome gene signature to predict Gleason 7 prostate cancer on an initial prostate needle biopsy

Presented at: 2015 Genitourinary Cancers Symposium (Orlando, Florida; February 2015)
Authors: M. J. Donovan, M. Noerholm, S. Bentink, S. Belzer, J. Skog, G. A. Brown, J. S. Cochran, V. O’Neill

View poster


 

To view more, click here

Exosome Diagnostics and ExoDx, are registered and unregistered trademarks of Exosome Diagnostics, Inc.

BSI-Assurance-Mark-ISO-13485-KEYB